DENTSPLY SIRONA Inc. (XRAY)
| Market Cap | 1.76B -29.2% |
| Revenue (ttm) | 3.64B -0.8% |
| Net Income | -546.00M |
| EPS | -2.73 |
| Shares Out | 199.35M |
| PE Ratio | n/a |
| Forward PE | 5.97 |
| Dividend | $0.16 (1.81%) |
| Ex-Dividend Date | Dec 26, 2025 |
| Volume | 5,182,762 |
| Open | 8.49 |
| Previous Close | 8.44 |
| Day's Range | 8.32 - 8.86 |
| 52-Week Range | 8.32 - 14.76 |
| Beta | 0.88 |
| Analysts | Hold |
| Price Target | 12.67 (+43.49%) |
| Est. Earnings | Nov 5, 2026 |
About XRAY
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as w... [Read more]
Financial Performance
In 2025, DENTSPLY SIRONA's revenue was $3.68 billion, a decrease of -2.98% compared to the previous year's $3.79 billion. Losses were -$598.00 million, -34.29% less than in 2024.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for XRAY stock is "Hold." The 12-month stock price target is $12.67, which is an increase of 43.49% from the latest price.
News
Dentsply Sirona price target lowered to $10 from $14 at Leerink
Leerink lowered the firm’s price target on Dentsply Sirona (XRAY) to $10 from $14 and keeps a Market Perform rating on the shares. The firm says there are very few…
Dentsply Sirona price target lowered to $12 from $14 at Piper Sandler
Piper Sandler lowered the firm’s price target on Dentsply Sirona (XRAY) to $12 from $14 and keeps a Neutral rating on the shares. The firm is updating its Dentsply model…
Wellspect HealthCare Announces U.S. Medicare Reimbursement Access for Surity™ Urinary Management Portfolio
MÖLNDAL, Sweden, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wellspect HealthCare today announced that the Surity™ portfolio, including the Surity™ Urinary Management System and Surity™ Female and Male External...
Dentsply Sirona Continues North American Commercial Expansion with Midwest Dental Agreement
The expanded relationship builds on a series of agreements announced this year, strengthening Dentsply Sirona's North American dealer network and giving more customers access to its products and techn...
Dentsply Sirona price target lowered to $10 from $13 at BMO Capital
BMO Capital analyst Vik Chopra lowered the firm’s price target on Dentsply Sirona (XRAY) to $10 from $13 and keeps a Market Perform rating on the shares after the management…
DENTSPLY SIRONA Transcript: 2026 Global Healthcare Conference
Leadership highlighted ongoing transformation, resource reallocation, and a 24-month turnaround plan. Strategic focus includes expanding sales channels, investing in clinical education and R&D, and enhancing digital workflows. Financially, sequential EPS growth is targeted, with long-term goals of market-level or better growth and improved cash flow.
Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Dentsply Sirona to Participate in the Baird 2026 Global Healthcare Conference
CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Baird 2026 Global ...
Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities
"I'll give you 950 billion reasons to buy bonds right now," says Thomas Hayes, who gives a contrarian take on why investors should bolster their portfolios in fixed income. He discusses the "seasonali...
Dentsply Sirona price target raised to $11 from $9 at Barclays
Barclays raised the firm’s price target on Dentsply Sirona (XRAY) to $11 from $9 and keeps an Underweight rating on the shares. The firm updated the company’s to reflect the…
New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence
New system completes the Surity™ portfolio of external catheters for both men and women Integrates into daily routines to help support management of urinary incontinence at home Designed to operate q...
Dentsply Sirona price target lowered to $15 from $17 at Barrington
Barrington lowered the firm’s price target on Dentsply Sirona (XRAY) to $15 from $17 and keeps an Outperform rating on the shares post the Q2 report. While Dentsply’s strategic decision…
Dentsply Sirona price target raised to $15 from $14 at Baird
Baird raised the firm’s price target on Dentsply Sirona (XRAY) to $15 from $14 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results…
Dentsply Sirona price target raised to $13 from $12 at BMO Capital
BMO Capital raised the firm’s price target on Dentsply Sirona (XRAY) to $13 from $12 and keeps a Market Perform rating on the shares.
DENTSPLY SIRONA Earnings Call Transcript: Q2 2026
Q2 2026 revenue declined 4.1% as reported, with flat adjusted EPS and strong cash flow boosted by tariff refunds. The Return-to-Growth plan is progressing, with investments in commercial capabilities and innovation expected to drive improvement, especially in Q4.
DENTSPLY SIRONA Slides: Q2 2026
DENTSPLY SIRONA has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
DENTSPLY SIRONA Earnings release: Q2 2026
DENTSPLY SIRONA released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
DENTSPLY SIRONA Quarterly report: Q2 2026
DENTSPLY SIRONA has published its Q2 2026 quarterly earnings report on August 6, 2026.
Dentsply Sirona backs FY26 adjusted EPS view $1.40-$1.50, consensus $1.42
Backs FY26 revenue view $3.5B-$3.6B, consensus $3.59B. The company said, “The Company is maintaining its 2026 outlook for net sales in the range of $3.5 billion to $3.6 billion and…
Dentsply Sirona reports Q2 adjusted EPS 52c, consensus 35c
Reports Q2 revenue $898M, consensus $889.84M. “2026 continues to be a year of decisive action as we execute our Return-to-Growth Action Plan,” said Dan Scavilla, President and Chief Executive Officer…
Dentsply Sirona Reports Second Quarter 2026 Results
News Summary Reported net sales of $898 million Delivered GAAP gross margin of 54.9%, GAAP diluted earnings per share of $0.18 Achieved adjusted gross margin of 56.4%, adjusted EBITDA margin of 21.3%,...
Dentsply Sirona price target raised to $14 from $13 at Piper Sandler
Piper Sandler raised the firm’s price target on Dentsply Sirona (XRAY) to $14 from $13 and keeps a Neutral rating on the shares. The firm notes the stock has recovered…
Dentsply Sirona expands relationship with Medline Sinclair
Dentsply Sirona (XRAY) announced an expansion of its long-standing relationship with Medline Sinclair. Effective September 1, Medline Sinclair will begin offering Dentsply Sirona’s technology portfoli...
Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship
CHARLOTTE, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- Dentsply Sirona, the world's largest diversified manufacturer of professional dental products and technologies, today announced an expansion of its l...
Dentsply Sirona to Host Second Quarter Conference Call on August 6th
CHARLOTTE, N.C., July 21, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and l...